Belli B, Patel A, Fan H
Department of Molecular Biology and Biochemistry, University of California, Irvine 92717.
J Virol. 1995 Feb;69(2):1037-43. doi: 10.1128/JVI.69.2.1037-1043.1995.
We recently showed that different routes of inoculation affect the leukemogenicity of the Mo+PyF101 variant of Moloney murine leukemia virus (M-MuLV). Intraperitoneal (i.p.) inoculation of neonatal mice with Mo+PyF101 M-MuLV greatly enhanced its leukemogenicity compared with subcutaneous (s.c.) inoculation. We previously also suggested that the leukemogenicity defect of Mo+PyF101 M-MuLV when inoculated s.c. may result from the inability of this virus to form env gene recombinant (mink cell focus-inducing [MCF]) virus. In this study, virus present in end-stage tumors and in preleukemic animals inoculated i.p. by Mo+PyF101 M-MuLV was characterized. In contrast to s.c. inoculation, all tumors from i.p.-inoculated mice contained high levels of recombinant MCF virus. Furthermore, Southern blot analyses demonstrated that the majority of the tumors contained altered Mo+PyF101 M-MuLV long terminal repeats. The U3 regions from several tumors with altered long terminal repeats were cloned by PCR amplification. Sequence analyses indicated that the M-MuLV 75-bp tandem repeat in the enhancer region was triplicated. This amplification was also previously observed in mice infected s.c. with a pseudotypic mixture of Mo+PyF101 M-MuLV and Mo+PyF101 MCF virus. The enhancer triplication was an early event, and it occurred within 2 weeks postinfection. Recombinant MCF viruses were not detected by Southern blot analyses until 4 weeks postinfection. Thus, the M-MuLV enhancer triplication event was initially important for efficient propagation of ecotropic Mo+PyF101 M-MuLV. The increased leukemogenicity following i.p. inoculation could be explained if the triplication enhances Mo+PyF101 M-MuLV replication in the bone marrow and bone marrow infection is required for recombinant MCF virus formation.
我们最近发现,不同的接种途径会影响莫洛尼鼠白血病病毒(M-MuLV)的Mo+PyF101变体的致白血病性。与皮下(s.c.)接种相比,用Mo+PyF101 M-MuLV对新生小鼠进行腹腔(i.p.)接种可大大增强其致白血病性。我们之前还提出,Mo+PyF101 M-MuLV皮下接种时致白血病性缺陷可能是由于该病毒无法形成env基因重组(貂细胞集落形成诱导[MCF])病毒。在本研究中,对终末期肿瘤以及通过Mo+PyF101 M-MuLV腹腔接种的白血病前期动物体内的病毒进行了特征分析。与皮下接种不同,腹腔接种小鼠的所有肿瘤都含有高水平的重组MCF病毒。此外,Southern印迹分析表明,大多数肿瘤含有改变的Mo+PyF101 M-MuLV长末端重复序列。通过PCR扩增克隆了几个长末端重复序列改变的肿瘤的U3区域。序列分析表明,增强子区域的M-MuLV 75 bp串联重复序列发生了三倍扩增。这种扩增在皮下感染Mo+PyF101 M-MuLV和Mo+PyF101 MCF病毒假型混合物的小鼠中也曾观察到。增强子三倍扩增是一个早期事件,发生在感染后2周内。直到感染后4周,Southern印迹分析才检测到重组MCF病毒。因此,M-MuLV增强子三倍扩增事件最初对于嗜亲性Mo+PyF101 M-MuLV的有效传播很重要如果三倍扩增增强了Mo+PyF101 M-MuLV在骨髓中的复制,并且重组MCF病毒的形成需要骨髓感染,那么腹腔接种后致白血病性增加就可以得到解释。